Paclitaxel trevatide
chemical compound
Paclitaxel trevatide (development codes NG1005 and GRN1005) is an experimental chemotherapy drug that is under development by Angiochem Inc, a Canadian biotech company. Phase II clinical trials have completed for several indications, and the company is preparing for phase III trials.
Paclitaxel trevatide is a paclitaxel-Angiopep-2 conjugate. Various Angiopep vectors have been composed and differ by their anti-cancer moieties. This has then been shown to be a prospective cancer therapy drug that can not only be conjugated to paclitaxel but also peptides, monoclonal antibodies, siRNA and many other biological materials. Paclitaxel trevatide has the potential to treat a variety of CNS diseases including glioma. Research has shown reduction in tumor growth in mice and rats with glioblastoma.
Mechanism of action
This drug was specifically designed to treat brain tumors. Because of the blood brain barrier (BBB), many cancer therapy drugs are prevented from passing through the brain capillaries into the parenchyma. Paclitaxel is generally prevented from reaching its target in the cell due to the presence of the efflux pump P-glycoprotein (P-gp) at the barrier.
“Paclitaxel trevatide” enters the record as chemical compound. Crown Archives preserves that source wording while asking what Paclitaxel, trevatide and chemical can confirm, complicate or overturn.
Why this record matters
“Paclitaxel trevatide” is worth following because a concise public description often conceals a longer documentary argument. Here, Paclitaxel, trevatide and chemical provides the most credible route into that argument.
Datasets, specimens, observations and peer-reviewed methods provide the appropriate test for the technical claims summarized here. The source revision retrieved here is dated Dec 27, 2025. The linked authority identifier is Q4652961. None of the 0 selected statements returned an explicit reference.
Current terminology should not be projected backward without checking the classification used when the underlying evidence was created. The lead is largely declarative, so disagreement and counter-evidence require a deliberate search beyond the opening account. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Check terminology, classification and the date of the cited evidence. Scientific names and technical consensus can change while older records retain historical value.
- Current terminology
- Classification context
- Finding cited technical literature
Primary datasets, specimen catalogues, standards bodies and the most recent peer-reviewed literature.
Three-step research path
- Establish the record: confirm the title “Paclitaxel trevatide”, its source revision and the description used here.
- Expand the search: follow Paclitaxel trevatide primary sources, Paclitaxel trevatide archive and Paclitaxel research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Paclitaxel trevatide”?
- Which observation, specimen, dataset or publication supports the account?
- Has classification or technical consensus changed since the cited source?
Search terms from this dossier
This entry incorporates text from “Paclitaxel trevatide” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.